Showing 4211-4220 of 9851 results for "".
- FDA Accepts Label Update for Suneva’s Plasma IQhttps://practicaldermatology.com/news/fda-accepts-label-update-for-sunevas-plasma-iq/2461061/Plasma IQ label, including the removal of the product's eye contraindication. The removal of this specific contraindication was due in part to a compilation of literature provided to the FDA showing the safety and efficacy of the ablative device on skin tissue, particular
- Neutrogena Announces New "Heroes of Skin Health Equity" Initiativehttps://practicaldermatology.com/news/neutrogena-announces-new-heroes-of-skin-health-equity-initiative/2461057/Neutrogena is launching its new Heroes of Skin Health Equity initiative, the brand’s latest effort aimed at closing the gap to skin health equity for those with Black and brown skin. The brand will publicly recognize the work of individuals who are striving to make
- Desert Harvest's Aloe Glide Receives NEA Seal of Acceptancehttps://practicaldermatology.com/news/desert-harvests-aloe-glide-receives-nea-seal-of-acceptance/2461056/Desert Harvest’s Aloe Glide has received the National Eczema Association (NEA) Seal of Acceptance, making it the first sexual lubricant to earn this seal. The NEA Seal appears on products approved by the association to help consumers identify and choose products that are suitable
- L'Oréal and Verily Partner to Advance Precision Skin Healthhttps://practicaldermatology.com/news/loreal-and-verily-partner-to-advance-precision-skin-health/2461048/L'Oréal and Verily, an Alphabet precision health company are joining forces to advance skin health. The partnership is expected to entail two programs aimed to better understand and characterize skin and hair aging mechanisms and to inform L'Oréal's precis
- UCB Releases Positive Top-line Results for Bimekizumab in Second Phase 3 Psoriatic Arthritis Studyhttps://practicaldermatology.com/news/ucb-releases-positive-top-line-results-for-bimekizumab-in-second-phase-3-psoriatic-arthritis-study/2461047/UCB’s bimekizumab performed well in a Phase 3 study of active psoriatic arthritis patients who were inadequate responders or intolerant to anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. Significantly more patients treated with bimekizumab achieved 50 percent or great
- DecisionDx-SCC Performs Well as a Risk-Stratification Tool in Patients with High-risk SCChttps://practicaldermatology.com/news/decisiondx-scc-performs-well-as-a-risk-stratification-tool-in-patients-with-high-risk-scc/2461039/Castle Biosciences, Inc’s DecisionDx-SCC can provide significant and independent prognostic value for stratifying metastasis risk in patients with cutaneous squamous cell carcinoma (SCC) with one or more risk factors (high risk), a new study shows. The study appears in&nb
- FDA Approves Pfizer's Cibinqo for Moderate-to-Severe AD in Adultshttps://practicaldermatology.com/news/fda-approves-pfizers-cibinqo-for-moderate-to-severe-ad-in-adults/2461037/Pfizer's Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, is now FDA approved for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including bi
- FDA Approves Rinvoq for Adults and Children 12 Years and Older with Refractory, Moderate to Severe ADhttps://practicaldermatology.com/news/us-fda-approves-rinvoq-for-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-ad/2461036/The FDA has given its nod to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including bio
- $511M SPAC Deal for Sunevahttps://practicaldermatology.com/news/511m-spac-deal-for-suneva/2461032/Suneva Medical, Inc. and Viveon Health Acquisition Corp., a special purpose acquisition company (SPAC), are joining forces to form a regenerative aesthetics company. Upon completion of the transaction, the combined company's securities are expected to be traded on the NYSE unde
- Allergan Aesthetics Completes Acquisition of Solitonhttps://practicaldermatology.com/news/allergan-aesthetics-completes-acquisition-of-soliton/2461013/It’s official: Allergan Aesthetics, an AbbVie company, completed its acquisition of Soliton, Inc. The addition of Soliton and its technology complements Allergan Aesthetics' portfolio of non-invasive body contouring treatments to now include the RESONIC device.